Menu

Banner Banner

Summary

Unmet need Technical performance Patient benefits
  • Inhaler errors are common in clinical practice and guidelines emphasise the importance of correct inhaler technique.1,2
  • One of the determinants of poor inhaler technique is the use of multiple inhaler types.1,3
  • Poor inhaler technique can lead to worsening outcomes.3
  • Many factors affect inhaler dose delivery and lung deposition.4-7
  • Aerodynamic particle size must be appropriate in order to ensure correct delivery of particles to the lung.8
  • Most patients can achieve the minimum inspiratory flow needed for dose delivery when using the Ellipta inhaler.9,10
  • Poor inhaler technique can lead to poor symptom control and increased unscheduled healthcare resource utilisation.1,11
  • Choice of inhaler should be tailored to a patient and take into account their preference and technique.1,12
  • Data has indicated that the Ellipta inhaler is easy to use and is associated with a low number of patients making critical errors.12,13 Clinical trials have also demonstrated the clinical efficacy of inhaled therapy delivered via the Ellipta inhaler.14,18

Continue your journey

Unmet need teaser

Unmet need

Explore the unmet need of inhaler therapy

GO TO UNMET NEED

Technical performance teaser

Technical performance

Explore the technical performance of inhalers

GO TO TECHNICAL PERFORMANCE

Patient benefits teaser

Patient Benefits

Explore the benefits of inhaled therapy for patients with COPD, including clinical efficacy

GO TO PATIENT BENEFITS

References

  1. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2022. Available at: https://goldcopd.org/2022-gold-reports-2/ Accessed March 2022.
  2. GINA. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2021. Available at: https://ginasthma.org/gina-reports/ Accessed March 2022.
  3. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. Int J Chron Obstruct Pulmon Dis. 2017;12:59-71.
  4. Fernández Tena A, Casan Clarà P. Arch Bronconeumol. 2012;48:240-246.
  5. Kleinstreuer C, Zhang Z, Donohue JF. Annu Rev Biomed Eng. 2008;10:195-220.
  6. Lavorini F, Magnan A, Dubus JC, et al. Respir Med. 2008;102:593-604.
  7. Rogliani P, Calzetta L, Coppola A, et al. Respir Med. 2017;124:6-14.
  8. Laube BL, Janssens HM, de Jongh FH, et al. Eur Respir J. 2011;37:1308-1331.
  9. Anderson M, Collison K, Drummond MB, et al. Int J Chron Obstruct Pulmon Dis. 2021;16:933-943.
  10. Prime D, Hamilton M, Taylor E. European Respiratory Journal. 2019;54:PA4230.
  11. Melani AS, Bonavia M, Cilenti V, et al. Respir Med. 2011;105:930-938.
  12. van der Palen J, Thomas M, Chrystyn H, et al. NPJ Prim Care Respir Med. 2016;26:16079.
  13. Collier DJ, Wielders P, van der Palen J, et al. Int J Chron Obstruct Pulmon Dis. 2020;15:1301-1313.
  14. Lipson DA, Barnacle H, Birk R, et al. Am J Respir Crit Care Med. 2017;196:438-446.
  15. Lipson DA, Barnhart F, Brealey N, et al. N Engl J Med. 2018;378:1671-1680.
  16. Maltais F, Ferguson GT, Feldman GJ, et al. Adv Ther. 2019;36:2434-2449.
  17. Feldman GJ, Sousa AR, Lipson DA, et al. Adv Ther. 2017;34:2518-2533.
  18. Alcázar Navarrete B, Boucot I, Naya I, et al. Pulm Ther. 2018;4:171-183.

©2022 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.

NX-GBL-UCV-WCNT-220002 | August 2022